

08.30 Registration, Networking and Exhibition Hall opens

Whittle Room, Floor 3

09.00 Welcome from One Nucleus: Harriet Fear, CEO, One Nucleus

09.10 - 10.45 Plenary Session

09.10 - 09.20 Introduction from the Chair, Glenn Crocker, CEO, BioCity

09.20 - 09.40 Opening Address: A neighbour's view of changes in the US Life Science and Healthcare market, Peter Brenders, CEO, BIOTECCanada

09.40- 10.00 Infrastructure investment and bio-incubation: The UK model, Martino Picardo, CEO, Stevenage Bioscience Catalyst

10.00 - 10.20 Making the world a smaller place when it comes to enabling enterprise collaboration, Stuart Barr, Director, HighQ Solutions

10.20 - 10.40 The Scrip guide to the winners and losers of 2011, Mike Ward, Head of Scrip Intelligence, Scrip

10.40- 10.45 Introducing the UKTI International Zone: Jane Grady, Head of Healthcare and Life Sciences Sectors Team, UK Trade and Investment

10.45 - 11.15 Tea/Coffee, Networking and Exhibitor Visits (Fleming Room and Benjamin Britten Lounge, Floor 3)

11.15 - 12.45 Parallel Streams

UKTI International Zone 1-2-1 Partnering	<b>St. James's Suite, Floor 4</b>	<b>Westminster Suite, Floor 4</b>	<b>Guild Room, Floor M</b>	
	<b>Stream A</b>	<b>Stream B</b>	<b>Session 1</b>	
	<b>A Paradigm Shift in Drug Development</b>	<b>Financing and Valuation in Medical Devices</b>	<b>Botanicals / Natural Products Stream</b>	
	<b>Thematic Leader: Dr Flic Gabbay, TranScrip Partners</b>	<b>Thematic Leader: Daniel Green, Phagenesis</b>	<b>Thematic Leader: Greer Deal, Global Regulatory Services, GRS</b>	
	<i>Introduction from Chair, Dr Flic Gabbay, TranScrip Partners</i>	<i>Introduction from the Chair, Daniel Green, Phagenesis</i>	<i>Introduction from the Chair, Prof. Peter Hylands, King's College London</i>	
	<i>Discovery for the Future: Small pharma thinking, Prof. Malcolm Young, CEO, e-Therapeutics</i>	<b>Thomas Warthoe, CEO, Atonomics</b>	<i>How genomics, NGS, and cloud computing can enhance phytomedicine in early stage research and development, Will Spooner, CTO and Founder, Eagle Genomics Ltd, UK</i>	
	<i>Discovery for the Future: Big pharma thinking, Dr Rick Cousins, GSK</i>	<b>Ewan Phillips, CEO, Deltex Medical</b>		
	<i>Pipelines of the Future, Prof. Clive Page PhD, Chairman, Verona Pharma</i>	<b>Henry Hyde-Thomson, Chairman, Anglo Scientific</b>	<i>Novel plant water-soluble components for food/cosmetic ingredients and Pharma use, Dr Robert Nash, Founder Director, Phytoquest Limited, UK</i>	
<i>Funding the Future - An overview, Richard Jones, CFO, Shield Therapeutics</i>	<b>Rowan Gardner, BioLauncher</b>			
<i>Licensing: The Future - An Overview, John Ansell, Director, John Ansell Consultancy</i>		<i>Cracked Eggs and tea: Linking veterinary and human health, Ray Cooper, Co founder, PhytoScience LLC</i>		
<i>Supporting the Future - Overview of the service sector and how it is changing, Graham Hughes, Ellera Scientific</i>	Q&A			
Q&A				

12.45 - 14.00 Lunch, Networking and Exhibitor Visits (Fleming Room and Benjamin Britten Lounge, Floor 3)

14.00 - 15.30 Parallel Streams

UKTI International Zone 1-2-1 Partnering	<b>St. James's Suite, Floor 4</b>	<b>Westminster Suite, Floor 4</b>	<b>Guild Room, Floor M</b>	<b>Whittle Room, Floor 3</b>
	<b>Stream A</b>	<b>Stream B</b>	<b>Session 2</b>	
	<b>Can Novel Proteins and Peptides Dominate Therapy in the Next Decade?</b>	<b>Influencing Progress for Life Sciences</b>	<b>Botanicals / Natural Products Stream</b>	<b>ABCEurope Infection &amp; Immunity Technology Showcase</b>
	<b>Thematic Leader: Keith Powell, Domainex</b>	<b>Thematic Leader: Nigel Gaymond, Chief Executive, BioIndustry Association</b>	<b>Thematic Leader: Greer Deal, Global Regulatory Services, GRS</b>	<b>Technology presentations</b>
	<i>Introduction from the Chair, Keith Powell, Domainex</i>	<i>Introduction from the Chair, Nigel Gaymond, BioIndustry Association</i>	<i>Introduction from the Chair, Prof. Peter Hylands, King's College London</i>	<i>Welcome and Introduction, Prof. Colin R. Howard, Royal Veterinary College</i>
	<i>The Future of therapy is Peptides, Dr Chris Ullman, Isogenica; Dr Arvind Hundal, Zealand Pharma</i>	<i>The importance of sector engagement to policymakers, David Smith</i>		<i>Encaging the pro-inflammatory danger by natural humoral immunity, Dr Anna Frostegård, Medirista Biotechnologies, Sweden</i>
	<i>Single domain antibody therapeutics from an in vivo platform, Mike Romanos, Crescendo Biologics</i>	<i>The BIA engagement with policymakers, Joseph Wildy, BIA</i>	<i>Unlocking the health potential of African medicinal plants, Denzil Phillips, Denzil Phillips International, UK</i>	<i>Immunotherapy of Cancer and Chronic Infection, Prof. Hans Stauss, UCL, UK</i>
	<i>The Future of therapy is Proteins, Ajay Mistry, Polytherics</i>	<i>R &amp; D Tax Credits, Phil Boyd, Syntaxin</i>	<i>Natural Products: Last Resort or Smarter Choice for Drug Discovery, Liam Evans PhD, CEO, Hypha Discovery Ltd</i>	
<i>The Future of therapy is None of the above, Dr Trevor Perrior, Domainex</i>	<i>Life Science Legislation, tbc</i>	<i>NIHR Clinical Research Networks: Supporting Industry to deliver clinical research in the NHS, Louise Forster, Industry Liaison Manager, NIHR Primary Care Research Network</i>	<i>Development of a novel food ingredient for the prevention of rotavirus infections, Prof. David Lembo, Rotalactis, Italy</i>	
	Q&A			
	<i>Workshop / Surgery - Bring your policy problems and have them answered by an expert panel, Lisa Urquhart, E P Vantage, Nigel Gaymond, BIA, Phil Boyd, Syntaxin, and Steve Bates, Genzyme</i>		<i>Development of novel antibiotic technology, Dr Heather Fairhead, Phico Therapeutics, UK</i>	
	Sum up			

15.30 - 16.00 Tea/Coffee, Networking and Exhibitor Visits (Fleming Room and Benjamin Britten Lounge, Floor 3)

16.00 - 17.30 Parallel Streams

UKTI International Zone 1-2-1 Partnering	<b>St. James's Suite, Floor 4</b>	<b>Westminster Suite, Floor 4</b>	<b>Guild Room, Floor M</b>	<b>Whittle Room, Floor 3</b>
	<b>Stream A</b>	<b>Stream B</b>	<b>Session 3</b>	
	<b>Clinical Research in the UK</b>	<b>Managing the Good, the Bad and the Ugly of Newsflow</b>	<b>Botanicals / Natural Products Stream</b>	<b>ABCEurope Infection &amp; Immunity Technology Showcase</b>
	<b>Thematic Leader: Tony Rees, Syne qua non Ltd</b>	<b>Thematic Leader: Edward Agne, Communications Strategy Group</b>	<b>Thematic Leader: Greer Deal, Global Regulatory Services, GRS</b>	<b>Technology presentations</b>
	<i>Introduction from Chair, Tony Rees, Syne qua non Ltd</i>	<b>Mike Ward, Head of Scrip Intelligence, Scrip</b>	<i>Introduction from the Chair, Prof. Peter Hylands, King's College London</i>	<i>Detection and monitoring of industrial workers for allergic rhinitis and asthma, Dr Paul Rodgers, ProteinLogic, UK</i>
	<i>The New Paradigm for Clinical Trial Outsourcing by Virtual Biotech Companies, Ewan Campbell, Director, The Clinical Trial Compay</i>	<b>Deborah Cockerill, SCIAD</b>	<i>East meets West with novel botanicals, Ian Scoular, Director of Business Development, Phynova Group Ltd, UK</i>	<i>Identification of a novel gene expression-based biomarker that predicts prognosis in autoimmune and inflammatory disease, Dr Paul Lyons, University of Cambridge, UK</i>
	<i>Functional Outsourcing as a Strategy for Clinical Development - Don't Put All Your Eggs in One Basket, Dr Jon Wood, Head, Biometrics and Reporting, Syne qua non</i>	<b>Nathan Nagel, Oncology Pharma</b>	<i>Regulations: Compliance and enforcement - the reality, Greer Deal, Director, Global Regulatory Services</i>	<i>A new concept in cancer vaccine immune monitoring: The detection of new immune response and epitope spreading under vaccination via peptide arrays, Dr Paul von Hoegen, JPT Peptide Technologies, Germany</i>
	<i>Outsourcing of Equipment. Automotive vs. Pharmaceutical, David Maughan, Managing Director, MESM</i>	<b>Lala Gregorek, Edison Investment Research</b>	<i>Counterfeiting - a global challenge, Ruth Thomson, Cambridge Consultants, UK</i>	<i>Development of a novel peptide for decolonisation of MRSA carriage, Dr Mathew Upton, University of Manchester, UK</i>
<i>Forcing Failure - Is it too Negative a Mind-Set for Your Development Programme? Dr Cyril Clarke, VP of Translational Medicine ICON Development Solutions</i>	<b>Jennifer Pierce, Charles Russell LLP</b>			
<i>Closing Questions and Remarks</i>	Q&A		<i>Conclusions, Ken Powell, Q-chip Ltd</i>	

17.30 - 19.00 Drinks Reception and Networking (Benjamin Britten Lounge, Floor 3)

19.00 Conference End

19.30 - 22.00 Genesis Awards Dinner, Church House Conference Centre - Guest Speaker, George Freeman MP, Government Advisor for Life Sciences